Bone Biologics (BBLG) Common Equity (2010 - 2026)

Bone Biologics (BBLG) has reported Common Equity for 16 consecutive years, with $5.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Common Equity rose 54.37% year-over-year to $5.4 million; the TTM figure through Dec 2025 stood at $5.4 million (up 54.37% YoY), while the FY2025 annual figure was $5.4 million, up 54.37% from the prior year.
• Common Equity retreated to $5.4 million in Q4 2025 per BBLG's latest filing, from $6.0 million in the prior quarter.
• Across five years, Common Equity topped out at $6.6 million in Q2 2025 and bottomed at -$15.1 million in Q3 2021.
• Historically, Common Equity has averaged $1.7 million across 5 years, with a median of $3.8 million in 2023.
• Annual changes were most pronounced in 2021 — Common Equity soared 148.02% — and 2023, when it tumbled 54.09%.
• Bone Biologics' Common Equity stood at $6.6 million in 2021, then fell by 9.55% to $5.9 million in 2022, then plunged by 51.13% to $2.9 million in 2023, then increased by 19.86% to $3.5 million in 2024, then surged by 54.37% to $5.4 million in 2025.
• Business Quant data shows BBLG's Common Equity at $5.4 million in Q4 2025, $6.0 million in Q3 2025, and $6.6 million in Q2 2025.